Navigation Links
Cochrane Review on primaquine to prevent malaria transmission
Date:7/3/2014

Researchers from the Cochrane Infectious Diseases Group, hosted at LSTM, conducted an independent review of the effects of adding a single dose of primaquine (PQ) to malaria treatment to prevent the transmission of the disease.

Mosquitoes become infected with Plasmodium falciparum when they ingest gametocyte-stage parasites from an infected person's blood. PQ is an antimalarial drug that does not cure malaria illness, but is known to kill the gametocyte stage of the P falciparum parasite, thus potentially limiting transmission to further humans. PQ is known to have potentially serious side effects for those who have the glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency, which is common in many malaria endemic regions.

In 2012 the World Health Organization (WHO) revised its recommendation for a single dose of PQ alongside treatment for P. falciparum malaria from 0.75 mg/kg down to 0.25mg/kg due to concerns about safety. The three authors looked at a total of 18 trials to examine the evidence of benefits and harms of using PQ in this way by evaluating whether PQ will reduce malaria transmission or the potential that it will reduce transmission based on infectious stages (gametocytes) in the blood. This fresh analysis grouped the studies by dose, to evaluate the effects of the low dose currently recommended by the WHO.

None of the included studies tested whether PQ added to malaria treatment reduced the community transmission intensity of malaria. Two studies showed that PQ at doses of 0.75 mg/kg reduced the number of mosquitoes infected after biting humans. PQ does reduce the proportion of people with gametocyte stages, the numbers of gametocytes and the duration of infectiousness (the period that gametocytes are detected in the blood) at doses of 0.4 mg/kg or above, but two trials at lower doses showed no effect.

Patricia Graves, from James Cook University in Cairns, said: "Evidence shows that at PQ doses of 0.4 mg/k
'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Zinc supplementation boosts immune system in children, Cochrane Review finds
2. UH makes Princeton Reviews Green List 3 years in a row
3. Research4Life greatly expands peer-reviewed research available to developing world
4. New peer-reviewed journal on big data launching in Fall 2012
5. New review outlines screening strategies for osteoporosis in young adults
6. Wiley launches new interdisciplinary review WIREs Energy and Environment
7. The Quarterly Review of Biology: Why some fats are worse than others
8. New book reviews the biology of synapses
9. Peer review option proposed for biodiversity data
10. New review associates vitamin D with lower rates of tooth decay
11. Beckers Spine Review Releases List of 50 Spine Surgeons & Specialists Researching Biologics for Spine Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... Research Institute (NHGRI), one of the National Institutes ... Sequencing Research Network will begin sequencing 12 more ... and several important insects, as part of its ... genome. , The National Advisory Council for Human ...
... a marvel of versatility, creating a variety of cells that ... out these tasks, immune cells follow a career path that ... in the May 2005 issue of Immunity, Fox Chase Cancer ... Dietmar J. Kappes, Ph.D., show that cell-receptor signaling strength influences ...
... the biological literature resides in full text articles, instead ... publicly available literature data mining tools. Most literature mining ... extracted from curated gene or protein databases. This is ... the many name variants which are used to refer ...
Cached Biology News:NHGRI targets 12 more organisms for genome sequencing 2NHGRI targets 12 more organisms for genome sequencing 3NHGRI targets 12 more organisms for genome sequencing 4NHGRI targets 12 more organisms for genome sequencing 5Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 2Fox Chase study shows that weakened T-cell receptor signals change T-cell lineage 3
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... and HEIDELBERG , Germany ... Addresses unmet need in treatment of millions of ... has been granted a patent in Europe ... patent supports Molecular Health,s discovery that EPHB4 is a novel ... promotes tumor growth. EPO stimulates the production of red blood ...
(Date:4/27/2015)... 2015 Diasome Pharmaceuticals, Inc. (“Diasome”) ... Joslin Diabetes Center (“Joslin”) to collaborate on the ... novel Hepatocyte Directed Vesicle (“HDV”) targeting system for ... , Located in Boston, Massachusetts, Joslin is the ... organization dedicated to the prevention, treatment and cure ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2
... Cylene Pharmaceuticals today announced,the initiation of a Phase ... carcinoid/neuroendocrine tumors (C/NET), which are malignant,cancers arising from ... "Quarfloxin (CX-3543) is a small molecule ... abnormal nucleoli of cancer cells, thereby,selectively inducing apoptotic ...
... PAREXEL International,Corporation (Nasdaq: PRXL ), ... the Company has been named the "Best Contract,Research ... award was,presented to PAREXEL at the fourth annual ... London, England. The Scrip Awards are designed to,celebrate ...
... Precision(R), Inc. a,leading provider of imaging, measurement, and ... that it will introduce a new imaging,system at ... conference with,twice the resolution of traditional microscopes. ... system developed by scientists at the, University of ...
Cached Biology Technology:Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes 2